Georgina V. Long, BSc, PhD, MBBS
The triplet of the PD-1 inhibitor spartalizumab, dabrafenib (Tafinlar), and trametinib (Mekinist) led to a complete response (CR) in more than 40% of patients with previously untreated advanced BRAF
V600–mutant melanoma, according to a pooled analysis of part 1 (run-in cohort) and part 2 (biomarker cohort) of the 3-part COMBI-i study.
In a total of 36 patients (9 from part 1 and 27 from part 2), first-line treatment with the triplet was associated with an overall response rate (ORR) of 78% by investigator assessment and a CR in 42% at a median follow-up of 19.9 months.1
At the time of (April 8, 2019), the median progression-free survival (PFS) was 23.7 months and the overall survival (OS) was not evaluable. Eight (22%) of the 36 patients had died.
... to read the full story